Hainan Poly Pharm: An indicative announcement on the suspension of trading of Puli Bonds and the suspension of share conversion
Hainan Poly Pharm: Announcement on the inability to disclose the 2023 Annual Report and the 2024 First Quarter Report and the suspension of trading of company stocks and convertible corporate bonds within the statutory period
Hainan Poly Pharm: An indicative announcement on the risk of the company's shares being subject to delisting risk
Hainan Poly Pharm: An indicative notice on the risk of not being able to disclose the 2023 Annual Report and the 2024 First Quarter Report within the statutory period
Hainan Poly Pharm: An indicative announcement on Pulley's bond conversion that is expected to trigger a downward revision of the conversion price
Hainan Poly Pharm: An indicative announcement on the deferred disclosure of the 2023 Annual Report
Puli Pharmaceuticals: Announcement on oseltamivir phosphate capsules obtaining marketing approval from the State Drug Administration
Puli Pharmaceuticals: Announcement on the Company's Response to the Letter of Concern on the Shenzhen Stock Exchange
Puli Pharmaceuticals: Announcement on receipt of a supervisory letter from an independent director
Prednisolone Pharmaceuticals: Announcement on the marketing approval of voriconazole injections from the Norwegian Medicines Agency
Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Finnish National Drug Administration
Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Swedish Medicines Agency
Puri Pharmaceuticals: Announcement on Daptomycin for injections obtained marketing approval from the German Federal Institute for Drugs and Medical Devices (BfArM)
Puli Pharmaceuticals: Announcement on the change of signed accountant
Puli Pharmaceuticals: Announcement on the conversion of convertible corporate bonds to shares in the first quarter of 2024
Puri Pharmaceuticals: Notice on submission of 8- (2-hydroxybenzamide) sodium caprylate (SNAC) pharmaceutical excipients to the U.S. DMF
Puri Pharmaceuticals: Announcement on obtaining marketing approval for injectable pantoprazole sodium from the Department of Pharmacy of the Ministry of Health of Israel
Puri Pharmaceuticals: Announcement on obtaining marketing approval for sodium nitrate injections in Germany
Puli Pharmaceuticals: Announcement on 2024 Interest Payments on Convertible Corporate Bonds
Puli Pharmaceuticals: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
No Data